October 25, 2020

The Niche

Knoepfler lab stem cell blog

Barbara J. Evans

2 min read

Day 2 of the Human Gene Editing Summit in DC (#GeneEditSummit) was quite interesting and added more depth to the meeting overall. For specific talks, see my two posts from yesterday here and here. Also see my top takeaways from Day 1. What were the top highlights of Day 2 of #GeneEditSummit? Somatic work. We shouldn’t only focus on germline human genetic modifications even if that is the most explosive issue. Yesterday we heard about striking developments in the arena of somatic/adult gene editing …Read More

2 min read

Now we have an interesting panel starting on questions of governance on human gene editing. This will focus on institutional and national levels of governance. Pilar N. Ossorio, University of Wisconsin, Madison, and Morgridge Institute for Research, is introducing the panel. Key question: how should emerging technologies being governed? Jonathan Kimmelman, from McGill, was the first speaker. How do we evaluate risk versus benefit with human genetic modification? Particularly how to answer this question in the context of clinical trials? Benefit should be defined as …Read More